Vertex’s Combo Drug Orkambi Faces FDA Doubts About Lumacaftor’s Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Advisory committee to consider whether Vertex should conduct new clinical trial comparing ‘breakthrough therapy’-designated, fixed-dose combo of lumacaftor and ivacaftor to ivacaftor alone in subgroup of cystic fibrosis patients.